Ran Zichel

Israel Institute for Biological Research

Papers

2

Total Citations

29

H-Index

2

About

Ran Zichel is a leading researcher in the field of botulinum neurotoxin (BoNT) countermeasures, with a focus on developing advanced antibody-based therapeutics and diagnostics. Their work addresses the critical challenge posed by BoNTs—among the most lethal substances known—by engineering serotype-specific monoclonal antibodies (mAbs) against the most clinically relevant serotypes (A, B, and E). A hallmark contribution is the evaluation of oligoclonal antibody preparations, demonstrating synergistic neutralizing effects that surpass individual mAbs, a breakthrough for more effective post-exposure treatments. Zichel’s pioneering trivalent immunization protocol, combined with a simultaneous differential robotic screen, enabled rapid, high-throughput development of serotype-specific mAbs, streamlining the path from discovery to application. With over 27 citations on their key 2014 study, Zichel’s work has significantly advanced the understanding of antibody synergy and practical therapeutic design. Their achievements include creating robust detection and neutralization tools that directly impact public health preparedness against botulism outbreaks and bioterrorism threats, marking them as a pivotal figure in toxinology and biodefense research.

Research Focus

Key Achievements

2
H-Index
2
Papers
29
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
Evaluating the Synergistic Neutralizing Effect of Anti-Botulinum Oligoclonal Antibody Preparations
27 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Israel Institute for Biological Research

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago